J Rheum Dis.  2020 Jan;27(1):22-29. 10.4078/jrd.2020.27.1.22.

Assessments of Functioning in Patients With Axial Spondyloarthritis

• Kiltz U
• Braun J

• KMID: 2471958
• DOI: http://doi.org/10.4078/jrd.2020.27.1.22

Abstract

A standardized assessment of functioning in patients with axial spondyloarthritis (axSpA) is necessary in order to assess clinical manifestations, disease activity, and physical and overall functioning as objectively as possible. The standardized assessment is based on domains such as disease activity, quality of life, functioning and employment but also on individual aspects such as pain, arthritis and enthesitis. Domains and individual aspects are mainly collected and better known as patient reported outcomes.

MeSH Terms

Arthritis
Employment
Humans
Quality of Life

Figure

• 

  Figure 1 Assessment of Spondyloarthritis International Society (ASAS)/Outcome Measures in Rheumatology Clinical Trials (OMERACT) Core Domains for ankylosing spondylitis (courtesy of www.asas-group.org).

• 

  Figure 2 ASDAS thresholds for disease status (A) and meaningful change (B) (courtsey of www.asas-group.org).

Reference

1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017; 390:73–84.

2. Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, et al. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Ann Rheum Dis. 2019; 78:1545–1549.

3. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68:777–783.

4. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27:361–368.

5. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken). 2012; 64:1415–1422.

6. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis. 2012; 71:1207–1211.

7. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999; 12:247–255.

8. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009; 7:25.

9. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol. 2002; 29:1420–1425.

10. Bedaiwi M, Sari I, Thavaneswaran A, Ayearst R, Haroon N, Inman RD. Fatigue in ankylosing spondylitis and nonradiographic axial spondyloarthritis: analysis from a longitudinal observation cohort. J Rheumatol. 2015; 42:2354–2360.

11. Kilic G, Kilic E, Ozgocmen S. Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis. Medicine (Baltimore). 2014; 93:e337.

12. Garrido-Cumbrera M, Delgado-Domínguez CJ, Gálvez-Ruiz D, Mur CB, Navarro-Compán V. Atlas Working Group. The effect of axial spondyloarthritis on mental health: results from the atlas. J Rheumatol. 2019; 46:1284–1289.

13. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis. 2001; 60:353–358.

14. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000; 27:613–622.

15. Haglund E, Bremander A, Bergman S, Jacobsson LT, Petersson IF. Work productivity in a population-based cohort of patients with spondyloarthritis. Rheumatology (Oxford). 2013; 52:1708–1714.

16. Chorus AM, Miedema HS, Boonen A, Van Der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis. 2003; 62:1178–1184.

17. Dagfinrud H, Mengshoel AM, Hagen KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis. 2004; 63:1605–1610.

18. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001; 44:1876–1886.

19. Kiltz U, van der Heijde D. Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2009; 27:4 Suppl 55. S108–S111.

20. Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol. 1996; 35:66–71.

21. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21:2286–2291.

22. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002; 359:1187–1193.

23. Song IH, Rudwaleit M, Listing J, Sieper J. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis. 2009; 68:1701–1707.

24. Essers I, Boonen A, Busch M, van der Heijde D, Keszei AP, Landewé R, et al. Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. Rheumatology (Oxford). 2016; 55:2014–2022.

25. Santos-Faria D, Dougados M, Gossec L, Perrot S, Moltó A. Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis. Rheumatol Int. 2019; 39:141–146.

26. Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, et al. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatology (Oxford). 2018; 57:1541–1547.

27. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004; 63:665–670.

28. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68:18–24.

29. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011; 70:47–53.

30. Molto A, Gossec L, Meghnathi B, Landewé RBM, van der Heijde D, Atagunduz P, et al. ASAS-FLARE study group. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis. 2018; 77:124–127.

31. Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Royston P, Landewé R. Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study. Ann Rheum Dis. 2015; 74:1218–1224.

32. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994; 21:1694–1698.

33. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994; 21:2281–2285.

34. Cieza A, Hilfiker R, Boonen A, van der Heijde D, Braun J, Stucki G. Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: a methodological exploration. Disabil Rehabil. 2009; 31:528–537.

35. Boonen A, Braun J, van der Horst Bruinsma IE, Huang F, Maksymowych W, Kostanjsek N, et al. ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis. 2010; 69:102–107.

36. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67:361–370.

37. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007; 22:1596–1602.

38. Smarr KL, Keefer AL. Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken). 2011; 63 Suppl 11:S454–S466.

39. van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, et al. GO-RAISE investigators. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014; 41:1095–1103.

40. Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 2007; 57:1050–1057.

41. Shim J, Jones GT, Pathan EMI, Macfarlane GJ. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and metaanalysis. Ann Rheum Dis. 2018; 77:1578–1584.

42. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford). 2010; 49:812–819.

43. Cawthon PM, Fullman RL, Marshall L, Mackey DC, Fink HA, Cauley JA, et al. Osteoporotic Fractures in Men (MrOS) Research Group. Physical performance and risk of hip fractures in older men. J Bone Miner Res. 2008; 23:1037–1034.

44. Kiltz U, Ahomaa E, Bühring B, Baraliakos X, Braun J. Clinically relevant deficits in performance tests in patients with Axial Spondyloarthritis(axSpA) – collecting questionnaires is insufficient. Arthritis Rheum. 2019; 71:Suppl 10. 1820.

45. van Weely SF, van Denderen CJ, van der Horst-Bruinsma IE, Nurmohamed MT, Dijkmans BA, Dekker J, et al. Reproducibility of performance measures of physical function based on the BASFI, in ankylosing spondylitis. Rheumatology (Oxford). 2009; 48:1254–1260.

46. van Weely SF, van Denderen JC, Steultjens MP, Nurmohamed MT, Dijkmans BA, Dekker J, et al. What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function. Rheumatology (Oxford). 2013; 52:1884–1889.

47. van Weely SF, van Denderen JC, Steultjens MP, van der Leeden M, Nurmohamed MT, Dekker J, et al. Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis. Arthritis Res Ther. 2012; 14:R52.

48. van Weely SF, Dekker J, Steultjens MP, van Denderen JC, Nurmohamed MT, Dijkmans BA, et al. Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests. J Rheumatol. 2015; 42:623–629.